Maple Rock Capital Partners Inc. Cuts Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Maple Rock Capital Partners Inc. reduced its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 7.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,208,741 shares of the company's stock after selling 350,660 shares during the quarter. Teva Pharmaceutical Industries accounts for about 2.8% of Maple Rock Capital Partners Inc.'s holdings, making the stock its 2nd biggest position. Maple Rock Capital Partners Inc. owned approximately 0.37% of Teva Pharmaceutical Industries worth $92,761,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Diversify Advisory Services LLC increased its position in shares of Teva Pharmaceutical Industries by 2.5% during the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock valued at $426,000 after acquiring an additional 496 shares during the last quarter. Thrivent Financial for Lutherans grew its position in Teva Pharmaceutical Industries by 0.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock valued at $4,964,000 after buying an additional 699 shares during the period. Townsquare Capital LLC increased its holdings in Teva Pharmaceutical Industries by 2.1% during the fourth quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock worth $885,000 after buying an additional 812 shares during the last quarter. Metis Global Partners LLC raised its position in Teva Pharmaceutical Industries by 6.7% in the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock worth $302,000 after acquiring an additional 860 shares during the period. Finally, DGS Capital Management LLC increased its stake in shares of Teva Pharmaceutical Industries by 6.8% in the third quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock worth $246,000 after purchasing an additional 872 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on TEVA shares. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Bank of America reduced their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. StockNews.com raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, April 23rd. UBS Group decreased their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Finally, Piper Sandler lifted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA traded up $0.60 during trading hours on Friday, reaching $16.22. 11,919,719 shares of the stock traded hands, compared to its average volume of 9,977,348. The company has a market capitalization of $18.39 billion, a P/E ratio of -11.19, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The company's 50-day simple moving average is $15.11 and its two-hundred day simple moving average is $17.49. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 52-week low of $12.47 and a 52-week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.